Accessibility Menu
 
Arrow-Thin-Down
S&P 500
6,990.26
+0.3%
+22.88
Arrow-Thin-Down
DJI
48,384.37
-0.3%
-151.62
Arrow-Thin-Down
NASDAQ
23,833.60
+0.8%
+194.52
Arrow-Thin-Down
Bitcoin
$74,436.00
-1.8%
-$1,393.70
Arrow-Thin-Down
AMZN
$247.62
-0.6%
-$1.40
Arrow-Thin-Down
GOOG
$331.34
+0.2%
+$0.76
Arrow-Thin-Down
META
$674.66
+1.8%
+$12.17
Arrow-Thin-Down
MSFT
$406.60
+3.4%
+$13.49
Arrow-Thin-Down
NVDA
$199.75
+1.6%
+$3.24
Arrow-Thin-Down
TSLA
$377.74
+3.7%
+$13.54
Most Active StocksDaily Stock GainersDaily Stock Losers

Threshold's Window of Success Reopens

Why Threshold popped today.

By Dave Williamson – Jan 23, 2013 at 9:14PM EST

Shares of Threshold Pharmaceuticals (NASDAQ: THLD) jumped up 15% today, bizarrely upon news that its competitor Celgene (CELG +0.00%) announced a set of successful phase 3 results. In this video, Motley Fool health-care analyst David Williamson tells investors what was behind this counterintuitive pop, and why it could be an excellent indicator for some of Threshold's own trials.

Read Next

About the Author

Dave Williamson
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
XMFGreenwave4
X@motleydavid

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services